title: Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia.
abstract: Tumor necrosis factor alpha antagonists have proven efficacious for a variety of autoimmune-mediated diseases. However, recent data have highlighted the risk of invasive fungal infections with their use. These agents are typically discontinued when infectious complications occur during therapy; however, the immune reconstitution inflammatory syndrome (IRIS) may be seen after drug cessation. We describe the 1st case of IRIS secondary to cryptococcal pneumonia after cessation of adalimumab.
authors.affiliation: Department of Medicine, University of Texas Health Science Center at San Antonio, 78229, USA.
authors.forename: Jose
authors.initials: J
authors.lastname: Cadena
authors.forename: George R
authors.initials: GR
authors.lastname: Thompson
authors.forename: Tony T
authors.initials: TT
authors.lastname: Ho
authors.forename: Edward
authors.initials: E
authors.lastname: Medina
authors.forename: Darrel W
authors.initials: DW
authors.lastname: Hughes
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Patterson
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003453:Cryptococcosis / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications* / Q000188:drug therapy; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000068879:Adalimumab